Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Hammel

Showing results (211-220 of 241) with videos related to

Pageof 25
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trialPascal Hammel, Portales Fabienne, Laurent Mineur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2020
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]Pascal Hammel, Fabienne Portales, Laurent Mineur, et al.
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD studyBenoit Rousseau, Marc Hilmi, Antoine Falcoz, et al.
The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2015
Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinomaRaphaël Maréchal, Jean-Baptiste Bachet, Annabelle Calomme, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2024
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 StudyPhilip A Philip, Vaibhav Sahai, Nathan Bahary, et al.
Nature Communications|June 13, 2023
Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinomaCharlie Saillard, Flore Delecourt, Benoit Schmauch, et al.
BMC Cancer|July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
The Lancet. Oncology|May 24, 2014
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trialDavid Malka, Pascale Cervera, Stéphanie Foulon, et al.
Pageof 25

Showing results (211-220 of 241) with videos related to

Sort By:
Pageof 25
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trialPascal Hammel, Portales Fabienne, Laurent Mineur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 11, 2020
Erratum to 'Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial' [European Journal of Cancer, Volume 124 (January 2020) Pages 91-101]Pascal Hammel, Fabienne Portales, Laurent Mineur, et al.
The New England Journal of Medicine|June 1, 2026
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic CancerEileen M O'Reilly, Zev A Wainberg, Andrew E Hendifar, et al.
Medrxiv : the Preprint Server for Health Sciences|July 3, 2026
Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD studyBenoit Rousseau, Marc Hilmi, Antoine Falcoz, et al.
The Lancet. Gastroenterology & Hepatology|January 19, 2020
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 studyPhilip A Philip, Jill Lacy, Fabienne Portales, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2015
Sonic hedgehog and Gli1 expression predict outcome in resected pancreatic adenocarcinomaRaphaël Maréchal, Jean-Baptiste Bachet, Annabelle Calomme, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2024
Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 StudyPhilip A Philip, Vaibhav Sahai, Nathan Bahary, et al.
Nature Communications|June 13, 2023
Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinomaCharlie Saillard, Flore Delecourt, Benoit Schmauch, et al.
BMC Cancer|July 29, 2023
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82)Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, et al.
The Lancet. Oncology|May 24, 2014
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trialDavid Malka, Pascale Cervera, Stéphanie Foulon, et al.
Pageof 25